Anne Hansen Ree

Professor of Oncology. Clinical Oncologist. Research Group Leader. Univ Oslo @UniOslo_MED Akershus Univ Hosp @Ahus_no Opinions personal

[Benjamin P. Geisler @ben_geisler]

New in @BrJCancer : post hoc analysis of METIMMOX - high TMB or BRAF-V600E may identify nivolumab responders in MSS metastatic CRC.

Hypothesis-generating, PFS only, prognostic vs. predictive unresolved. But a signal worth pursuing. 🧬

https://t.co/QQoA5GlNCu

[Yakup Ergün @dr_yakupergun]

#ASCO25 @NEJM
BREAKWATER: Encorafenib + cetuximab + mFOLFOX6 vs standard care in 1L BRAF V600E mCRC

PFS➡️12.8 vs 7.1 mo✅️
OS➡️ 30.3 vs 15.1 mo✅️👏

💥For one of the hardest-to-treat mCRC subtypes, this triplet shows substantial survival benefit.

https://t.co/dzjsTD9wiF

[Anne Hansen Ree @anne_h_ree]

Thank you Norw. Cancer Society, for believing once again in the METIMMOX concept (oxaliplatin & #ICPI) for #MSS #CRC abdominal mets, 4th time: METIMMOX-1 funded 2016, METIMMOX-2 funded 2020 & 2022, METIMMOX-3 funded today! 💥 Precision Oncology when it really matters (1L Tx) 🎯

[Benjamin P. Geisler @ben_geisler]

Here's a @DagensMedisin article (in Norwegian) about @anne_h_ree et al.'s #ESMO24 poster on subgroups of MSS/pMMR mCRC pts who might benefit from PD1/PDL1 inhibition:

https://t.co/zIMWFBj2K2

[Benjamin P. Geisler @ben_geisler]

Attending #ESMO24 w/ @anne_h_ree, Paula Bousquet, & Sebastian Meltzer to present on the value of treating MSS/pMMR metastatic colorectal cancer w/ immunotherapy and - critically - the role of biomarkers

#ESMO2024

[Anne Hansen Ree @anne_h_ree]

The utterly hard-to-treat metastatic #CRC : #MSS #pMMR #BRAF #V600E #livermets , given #nivolumab #ICB #ICI #ICPI following #immunogenic short-course #oxaliplatin based chemo, resulting in durable #CR. The #METIMMOX study 🇳🇴

[Anne Hansen Ree @anne_h_ree]

https://t.co/ARbQmUoyhX
(Fig 2!)
The utterly hard-to-treat met #CRC : #MSS #pMMR #BRAF #V600E #livermets , given #nivolumab #ICB #ICI #ICPI following #immunogenic short-course #oxaliplatin based chemo, resulting in durable #CR. The #METIMMOX study 🇳🇴

[ESMO - Eur. Oncology @myESMO]

#ESMOGI24: Do recent advances offer hope for mismatch repair-proficient and MSS #CRC pts who have a lower mutational burden and have historically been less responsive to immunotherapy?
Read the opinion by @MyriamChalabi on #ESMODailyReporter to find out
📌https://t.co/s9vDxfCXG2

[Anne Hansen Ree @anne_h_ree]

https://t.co/Fe0EniUZ1B
What's the next step in immuno-oncology for CRC? (note: you need to understand Norwegian (trøndersk) to apprehend my view in this news flash) #ASCO24 #CRC #MSS #MSI #IO @Ahus_no @UniOslo_MED

[Vinay Prasad MD MPH @VPrasadMDMPH]

We had a full house yesterday and back today with a different lecture.
Open to all. 4-6. Omni Hotel. 3rd floor. Chicago. #ASCO24 #asco2024

[MalmbergLab @MalmbergLab]

Love this tool developed by @EivindAsk. We use it for all complex flow/mass cytometry projects with lots of metadata. MetaGate: Interactive analysis of high-dimensional cytometry data with metadata integration: Patterns https://t.co/FlVHk9nXnu

[Anne Hansen Ree @anne_h_ree]

https://t.co/0P555CYYy1
Alternating = de-intensified oxaliplatin chemo & nivolumab, 1L Tx abdominal mets #MSS #pMMR #CRC - beneficial for subgroup. 16% CR! Long PFS! Curious who’s in that tail? Stay tuned! (we’ll tell soon)

[Anne Hansen Ree @anne_h_ree]

https://t.co/JZwH5LDV0z
Alternating = de-intensified #oxaliplatin & #nivolumab, 1L Tx for abdominal mets #MSS #pMMR #CRC - no better/worse than SoC chemo but beneficial for subgroup. 16% CR! Long PFS. Curious who’s in subgroup? Stay tuned! (we’ll tell soon)

[Anne Hansen Ree @anne_h_ree]

Another METIMMOX-1 (#MSS #CRC) poster, this time at #AACR2024. Precision Oncology when it really matters! (1L Rx) The convincing PFS curves behind my back – will remain a little secret until full publication 😉

[Anne Hansen Ree @anne_h_ree]

#GI24 The METIMMOX concept #CRC #MSS #ICI #ICB continues to reveal new and previously unrecognized insights into #IO. Here, Dr Sebastian Meltzer presents how he (w/ collaborators) is propelling this important science for the best of our patients.

[Ibrahim Halil SAHIN, MD @IbrahimSahinMD1]

Congratulations to new @ASCO leadership ‼️

Great news for academia and nice to see diversity at the leadership level ‼️

Congratulations ‼️
#DrEricSmall
@DrChoueiri
@JhanelleGray
@clarissamathias
@AbbyRosenbergMD
@CharuAggarwalMD
@KimmieNgMD

[Anne Hansen Ree @anne_h_ree]

Delighted at 20th Portuguese Oncology Congress discussing “Off-label therapy based on biomarkers: is it cost-effective as last-line treatment?” (answer: No!) Million thanks for hospitality, congress dinner at Forte da Cruz Estoril, light therapy when dark/cold November at home.

[MalmbergLab @MalmbergLab]

Brilliant @EivindAsk developed MetaGate: Interactive Analysis of High-Dimensional Cytometry Data with Meta Data Integration. This tool will help you if you have a large flow/mass cytometry dataset and associated clinical meta data @CoE_PRIMA @UniOslo_MED https://t.co/MCqSPo7vzI

[Anne Hansen Ree @anne_h_ree]

#ESMO23- Dr. Sebastian Meltzer presenting a for-free biomarker (🤑CRP) that selects met-MSS #CRC pts with highly extended PFS to 1L oxaliplatin + ICB (#nivolumab). Sustainable Precision Oncology = biomarker w/o costs, huge pt group, when really matters (1L)!

[Mark Lawler @QUBCancerProf]

See our landmark study highlighting gender inequity in female cancer research leadership in Europe. Results for research powerhouses v poor. UK: 33% Germany/Switzerland: 25%. Data do not lie. Must act quickly and decisively to reverse this injustice https://t.co/h5RTpInHIE